Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib
Figure 1
The box plots show the distribution of the average SUV1 and SUV1max values by conventional response evaluation according to RECIST criteria for the group of nonprogressive patients (PR + SD) versus patients with PD with an approximate value of 0.06553 and 0.07785, respectively.